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Accepted 17 February 2012A 26-year-old, primigravid woman was referred for genetic
counseling at 16 weeks of gestation because of maternal
osteogenesis imperfecta (OI) type I. She was 158 cm tall and
had a body weight of 51 kg. She had blue sclerae and was
known to have a mild form of OI type I; her father and sister
were also affected. She had sustained fractures of distal
phalanx of the left thumb and left radius. At 23 years of age,
cyclical intravenous bisphosphonate (pamidronate) had been
started because of recurrent fractures and bone pain.
The treatment with pamidronate was given at a dose of 15 mg/
month. Pamidronate therapy was ceased 1 month before the
pregnancy. Prenatal ultrasound was unremarkable, and the
fetal long bones were normal. The woman underwent
amniocentesis at 16 weeks of gestation, and cytogenetic
analysis revealed a karyotype of 46,XY. Level II ultrasound
follow-ups in the third trimester showed a normal fetus with
no bony abnormalities. At 37 weeks of gestation, she delivered
a 2840-g boy uneventfully via the vaginal route. The baby was
53 cm tall and had blue sclerae, but was morphologically
normal with no fractures. Neither the mother nor her son had
hypocalcemia postpartum.* Corresponding author. Department of Obstetrics and Gynecology, Mackay
Memorial Hospital, 92, Section 2, Chung-Shan North Road, Taipei, Taiwan.
E-mail address: cpc_mmh@yahoo.com (C.-P. Chen).
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doi:10.1016/j.tjog.2012.04.029At the age of 4 years, the son suffered a fracture of the right
humerus. He started intravenous pamidronate therapy at the
age of 8 years. Molecular analysis revealed that both the
mother and her son had a heterozygous deletion mutation of
c.1380delT in exon 21 of the COL1A1 gene resulting in
a functional null allele (Fig. 1). The mutation caused
a frameshift (p.G461AfsX79), introducing 78 novel residues at
codon 461 and resulting in a premature termination codon that
removed all the following amino acids of the protein. Six
months after delivery, the woman’s bone mineral density
of lumbar spine (L2-L4) was checked and found to be 0.847
g/cm2 (e2.59 SD from T-score), and she started intravenous
pamidronate therapy at 30 mg/month. Eighteen months after
the first pregnancy, the woman ceased pamidronate therapy
and started oral bisphosphonate therapy with alendronate
70 mg/week until 4 months before her second pregnancy at the
age of 30 years. During the second pregnancy, prenatal
ultrasound was normal, and she did not undergo any invasive
prenatal diagnosis. At 38 weeks of gestation, she delivered
a 3838-g healthy boy uneventfully via the vaginal route. The
baby was normal and was not affected with OI. Both the
mother and the normal son remained well 5 years postpartum.
The present case provides evidence for no adverse maternal
and fetal outcome after long-term bisphosphonate treatment
before conception in maternal OI type I. Bisphosphonates
inhibit osteoclast activity and suppress bone resorption bycs & Gynecology. Published by Elsevier Taiwan LLC. All rights reserved.
Fig. 1. Molecular analysis of the mother and her affected son shows that both
individuals have a heterozygous deletion of c.1380delT in exon 21 in the
COL1A1 gene resulting in a functional null allele.
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biosynthesis [1e3]. Bisphosphonates have been used in pre-
venting bone loss in the disorders of glucocorticoid-associated
osteoporosis, OI and hypercalcemia associated with malig-
nancy. The safety of bisphosphonates inwomen of child-bearing
age raises concerns that the fetus may potentially be exposed to
bisphosphonates released from the maternal bone if the mother
received bisphosphonates before conception, or directly trans-
mitted from the placenta if the mother receives bisphosphonates
during pregnancy [4e6]. Therefore, it has been advised that all
bisphosphonates are relatively contraindicated in females of
reproductive age [7]. However, recent studies have shown that
preconceptional and first-trimester use of bisphosphonates may
not pose substantial fetal risks [8e11]. Munns et al. [8] first
reported no adverse maternal and fetal outcome in two women
with OI type I and IV who received long-term pamidronate
treatment before conception. Chan and Zacharin et al. [9] foundno evidence for adverse effects of pre-pregnancy pamidronate
on maternal and fetal health in three women with polyostotic
fibrous dysplasia and in onewomanwithOI type IV.Djokanovic
et al. [10] reviewed 51 published cases of women exposed to
bisphosphonates before or during pregnancy and found that
none gave birth to infants with skeletal abnormalities or other
congenital malformations. Levy et al. [11] followed 21 women
exposed to bisphosphonates for 3 months or less before preg-
nancy in comparison with 21 matched controls and found no
fetal risks in the preconceptional and first-trimester use of
bisphosphonates. Our observation adds to the list of uncompli-
cated pregnancy outcome following in utero exposure to
bisphosphonates.
The present case also provides evidence for uncomplicated
pregnancy outcome of vaginal delivery for affected mothers and
fetuseswith non-lethal types ofOI. In a study of 167 pregnancies
with fetuses affected byOI, Cubert et al. [12] found that cesarean
delivery did not decrease the fracture rate at birth in the infants
with nonlethal forms and did not prolong survival for the infants
with lethal forms and suggested that cesarean delivery should be
reserved for standard obstetric indications in pregnancy with
fetal OI. In cases of maternal OI with mild clinical features,
vaginal delivery can be achieved. In a review of 15 pregnancies
with maternal OI, Key and Horger [13] found that 60% (9/15)
were delivered vaginally, and 40% (6/15) were delivered
abdominally because of cephalopelvic disproportion, twins,
a fragile fetus and previously fractured or deformed pelvis.
Although vaginal delivery in maternal OI type I is relatively
safe, careful obstetric surveillance is needed, and attention
should be paid to uterine rupture because of the decreased
amount of collagen in myometrium, postpartum hemorrhage as
a result of uterine atony, lacerations and impaired platelet
aggregation, and neonatal fracture associated with OI [13e19].
Acknowledgments
This work was supported by research grants NSC-97-2314-
B-195-006-MY3 and NSC-99-2628-B-195-001-MY3 from the
National Science Council, and MMH-E-100-04 from Mackay
Memorial Hospital, Taipei, Taiwan.
References
[1] Fleisch H. Bisphosphonates: mechanisms of action. Endocr Rev 1998;19:
80e100.
[2] Fisher JE, Rogers MJ, Halasy JM, Luckman SP, Hughes DE,
Masarachia PJ, et al. Alendronate mechanism of action: geranylgeraniol,
an intermediate in the mevalonate pathway, prevents inhibition of oste-
oclast formation, bone resorption, and kinase activation in vitro. Proc
Natl Acad Sci USA 1999;96:133e8.
[3] Halasy-Nagy JM, Rodan GA, Reszka AA. Inhibition of bone resorption
by alendronate and risedronate does not require osteoclast apoptosis.
Bone 2001;29:553e9.
[4] Graepel P, Bentley P, Fritz H, Miyamoto M, Slater SR. Reproduction
toxicity studieswith pamidronate.Arzneimittelforschung1992;42:654e67.
[5] Khan SA, Kanis JA, Vasikaran S, Kline WF, Matuszewski BK,
McCloskey EV, et al. Elimination and biochemical responses to intra-
venous alendronate in postmenopausal osteoporosis. J Bone Miner Res
1997;12:1700e7.
307C.-P. Chen et al. / Taiwanese Journal of Obstetrics & Gynecology 51 (2012) 305e307[6] Marini JC. Do bisphosphonates make children’s bones better or brittle? N
Engl J Med 2003;349:423e6.
[7] McKenna M, Mansfield JC. Safety of bisphosphonates in women of child
bearing age. Aliment Pharmacol Ther 2009;29:1214e5.
[8] Munns CFJ, Rauch F, Ward L, Glorieux FH. Maternal and fetal outcome
after long-term pamidronate treatment before conception: a report of two
cases. J Bone Miner Res 2004;19:1742e5.
[9] Chan B, Zacharin M. Maternal and infant outcome after pamidronate
treatment of polyostotic fibrous dysplasia and osteogenesis imperfecta
before conception: a report of four cases. J Clin Endocrinol Metab 2006;
91:2017e20.
[10] Djokanovic N, Klieger-Grossmann C, Koren G. Does treatment with
bisphosphonates endanger the human pregnancy? J Obstet Gynaecol Can
2008;30:1146e8.
[11] Levy S, Fayez I, Taguchi N, Han J-Y, Aiello J, Matsui D, et al. Pregnancy
outcome following in utero exposure to bisphosphonates. Bone 2009;44:
428e30.
[12] Cubert R, Cheng EY, Mack S, Pepin MG, Byers PH. Osteogenesis
imperfecta: mode of delivery and neonatal outcome. Obstet Gynecol
2001;97:66e9.[13] Key TC, Horger 3rd EO. Osteogenesis imperfecta as a complication of
pregnancy. Obstet Gynecol 1978;51:67e71.
[14] Carlson JW, Harlass FE. Management of osteogenesis imperfecta in
pregnancy. A case report. J Reprod Med 1993;38:228e32.
[15] Sharma A, George L, Erskin K. Osteogenesis imperfecta in pregnancy:
two case reports and review of literature. Obstet Gynecol Surv 2001;56:
563e6.
[16] Krishnamoorthy U, Vausse S, Donnai P. Management of pregnancy
complicated by maternal osteogenesis imperfecta. Report of a case with
uterine rupture. J Obstet Gynaecol 2002;22:316.
[17] Di Lieto A, Pollio F, De Falco M, Iannotti F, Mascolo M, Somma P, et al.
Collagen content and growth factor immunoexpression in uterine lower
segment of type IA osteogenesis imperfecta: relationship with recurrent
uterine rupture in pregnancy. Am J Obstet Gynecol 2003;189:594e600.
[18] Christodoulou S, Freemont AJ, McVey R, Vause S. Prospective
comparative case study of uterine collagen in a woman with osteogenesis
imperfecta type 1 who had previously ruptured her uterus. J Obstet
Gynaecol 2007;27:738e9.
[19] Litos M, Michala S, Brown R. Osteogenesis imperfecta and pregnancy.
Eur J Obstet Gynecol Reprod Biol 2008;136:126e7.
